New PET scan agent aims to spot cancers more precisely
NCT ID NCT07552467
First seen Apr 29, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study is testing a new radioactive imaging agent that targets a protein called LRRC15, found on many cancer cells. Researchers will use PET scans to see if this agent can better detect and stage cancers like pancreatic, breast, lung, and others. The trial includes 26 healthy volunteers and cancer patients to check safety and how the agent spreads in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital, China
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LRRC15-targeted PET radiotracer (diagnostic imaging agent)
What this could lead to
If successful, this could provide a more accurate way to diagnose and stage several types of cancer, helping doctors choose better treatments.
What could go wrong
This is an early-phase study with only 26 participants, so results may not apply broadly. The imaging agent's safety and effectiveness are still being evaluated.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.